Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
This page provides a historical news archive for ZimVie Inc. (formerly Nasdaq: ZIMV), a company that described itself as a global life sciences leader in the dental and dental implant market. The news coverage reflects ZimVie’s activities while it was a publicly traded manufacturer and developer of dental implants, biomaterials, and digital workflow solutions for tooth replacement and restoration procedures.
Readers can review company-issued announcements on topics such as quarterly financial results, strategic agreements, product launches, and corporate transactions. For example, ZimVie reported first and second quarter 2025 financial results, including net sales from continuing operations and non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share. The company also communicated guidance for full-year financial performance while it remained public.
The archive includes news about ZimVie’s role in digital dentistry, such as the launch of the RealGUIDE dental implant software suite and the Implant Concierge service in Japan. These releases describe a digital implant ecosystem that supports implant planning, surgical guide design, and restorative workflows, as well as virtual outsourcing services for implant treatment planning and guided surgery. Other news items highlight an exclusive distribution agreement with Osstem Implant in China, under which Osstem Implant has exclusive commercial responsibility for ZimVie implant systems in the Chinese market.
A significant portion of the news flow in 2025 relates to ZimVie’s agreement to be acquired by an affiliate of ARCHIMED. The company announced the definitive merger agreement, subsequent stockholder approval at a special meeting, and the completion of the transaction. In its October 20, 2025 release, ZimVie stated that, following the closing of the acquisition, its common stock no longer trades on the Nasdaq exchange and the company became privately held. Investors and researchers can use this news history to understand ZimVie’s strategic direction, financial communication, and the steps leading to its transition from a listed company to a private entity.
ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:
1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.
2. New restorative design workflows to meet evolving clinic and dental laboratory needs.
3. Amplified CAD workflows for creating attractive implant dentistry designs.
4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.
5. Cloud-based design libraries for improved accessibility.
The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.
ZimVie Inc. (Nasdaq: ZIMV) has announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio, following FDA 510(k) clearance. This launch expands ZimVie's end-to-end prosthetic offerings in the dental market. The GenTek portfolio, first introduced in Europe in 2019, includes Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products for digitally driven CAD/CAM restorations.
Designed to mate with ZimVie implant systems, GenTek components ensure a perfect fit and tight seal for long-term aesthetic and functional restorations. The company anticipates strong demand in the U.S. market, following the product's success in Europe.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its second quarter 2024 financial results after market close on Thursday, August 1, 2024. The company management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can register for the call online, with registration recommended more than 15 minutes before the call starts. A replay of the webcast will be available on the company's investor relations website.
On May 16, 2024, ZimVie, a global leader in the dental market, announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Jaws & Paws Conference on May 30, 2024, at 11:30 a.m. Eastern Time, and at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties can access a live webcast of these presentations through the 'Investors' section on ZimVie's website.
ZimVie Inc. (Nasdaq: ZIMV) reported third party net sales of $118.2 million, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million for the first quarter of 2024. The company completed the sale of its spine business for $375 million, repaid $275 million of debt, and is now focusing on its dental market leadership.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.